Lotte Biologics will attend CPHI Milan 2026, BioJapan 2026 and World ADC San Diego in October as it seeks new contract manufacturing deals and broader global partnerships. CPHI Milan will take place in Milan from October 6–8, BioJapan in Yokohama from October 7–9 and World ADC San Diego in California from October 12–15. At CPHI Milan, the company will showcase the large-scale commercial manufacturing capabilities of its Songdo Bio Campus and its Han-Mi Dual Site, linking production facilities in the United States and South Korea. It will also present its dual-antibody technology and hold partnering meetings with global pharmaceutical and biotechnology companies. At BioJapan, Lotte Biologics will highlight production automation and digital systems, including its Automated Manufacturing Control System, Digital Twin and Computational Fluid Dynamics simulation technologies, to emphasize quality stability and manufacturing efficiency for Asian clients. At World ADC San Diego, it will promote its proprietary antibody-drug conjugate platform and seek to expand its ADC business. Lotte Biologics has disclosed four order wins this year and received approval in June to use the first production plant at the Songdo Bio Campus. A company official said the company will continue pursuing global partnerships to attract clients, expand orders and strengthen its global competitiveness.